Recordati Industria Chimica e Farmaceutica SpA AAQS 2024
Recordati Industria Chimica e Farmaceutica SpA AAQS
10
Simbol
REC.MI
ISIN
IT0003828271
WKN
A0EABR
Recordati Industria Chimica e Farmaceutica SpA ima trenutni AAQS 10. Visok AAQS se lahko šteje za pozitiven pokazatelj, da se podjetje uspešno razvija. Vlagatelji lahko predvidevajo, da je podjetje na dobri poti k ustvarjanju dobička. Po drugi strani pa je pomembno primerjati AAQS delnice Recordati Industria Chimica e Farmaceutica SpA z dobičkom, ki ga ustvari, in z drugimi podjetji v isti panogi. Visok AAQS ni absolutno zagotovilo za pozitivno prihodnost. Le tako se lahko pridobi celovita slika o uspešnosti podjetja. Da bi bolje ocenili razvoj podjetja, je pomembno, da AAQS primerjamo z drugimi podjetji v isti panogi. Na splošno bi morali vlagatelji AAQS podjetja vedno obravnavati v povezavi z drugimi finančnimi kazalci, kot so dobiček, EBIT, denarni tok in drugi, da bi sprejeli utemeljeno investicijsko odločitev.
Recordati Industria Chimica e Farmaceutica SpA Aktienanalyse
Kaj počne Recordati Industria Chimica e Farmaceutica SpA?
Recordati Industria Chimica e Farmaceutica SpA is an Italian pharmaceutical company based in Milan. The company was founded in 1926 by Giovanni Recordati and now has branches in many countries worldwide. Recordati's business model is based on the development, production, and marketing of drugs for various therapeutic areas. The company focuses particularly on therapy areas such as cardiology, urology, gastroenterology, pneumology, and hematology. Recordati operates in four business areas: Innovative Medicines, OTC Medicines, Generics, and Licensed Products. In the area of innovative medicines, the company specializes in the development of new active substances for the treatment of rare diseases. In the OTC Medicines area, Recordati specializes in the manufacture and marketing of over-the-counter drugs used to treat mild to moderate complaints. The generics area includes the production and marketing of generic products with the aim of influencing price development in the market. In the Licensed Products area, Recordati collaborates with other companies and takes over the marketing of their products in certain regions. Some of Recordati's best-known products include Cariprazine (an antipsychotic), Urolith (a preventive treatment for kidney stones), Zanipress (a treatment for hypertension), and Fokusin (a treatment for benign prostatic hyperplasia). Recordati is also committed to improving access to life-saving medications worldwide. The company engages in collaborations with international organizations such as the Global Alliance for TB Drug Development and supports the WHO's "Target Product Profiles" initiative. In 2019, Recordati Industria Chimica e Farmaceutica SpA achieved sales of around 1.4 billion euros in over 90 countries. The company employs about 4,200 people worldwide, including approximately 500 researchers and developers. In terms of future direction, Recordati sees continued high potential for growth and expansion, particularly through targeted investments in research and development. The company relies on close cooperation with other partners within the industry and the exploration of new markets and therapeutic areas. Recordati Industria Chimica e Farmaceutica SpA ist eines der beliebtesten Unternehmen auf Eulerpool.com.Pogosta vprašanja o delnici Recordati Industria Chimica e Farmaceutica SpA
Delniški varčevalni načrti ponujajo privlačno možnost za vlagatelje, da dolgoročno zgradijo premoženje. Eden glavnih prednosti je tako imenovani učinek povprečenja stroškov: Z rednim vlaganjem fiksnega zneska v delnice ali delniške sklade se avtomatsko kupi več enot, ko so cene nizke, in manj, ko so visoke. To lahko vodi do ugodnejše povprečne cene na enoto s časom. Poleg tega delniški varčevalni načrti omogočajo tudi malim vlagateljem dostop do dragih delnic, saj se lahko pridružijo že z majhnimi zneski. Redna investicija tudi spodbuja disciplinirano investicijsko strategijo in pomaga izogibati se čustvenim odločitvam, kot so impulzivno kupovanje ali prodaja. Poleg tega vlagatelji profitirajo od potencialne rasti vrednosti delnic kot tudi od izplačil dividend, ki se lahko reinvestirajo, kar povečuje učinek obrestnega obrestovanja in s tem rast investiranega kapitala.
Andere Kennzahlen von Recordati Industria Chimica e Farmaceutica SpA
Naša analiza delnic Recordati Industria Chimica e Farmaceutica SpA Prihodki vključuje pomembne finančne kazalnike, kot so prihodki, dobiček, razmerje cena/dobiček (KGV), razmerje cena/prihodki (KUV), EBIT ter informacije o dividendah. Prav tako preučujemo aspekte, kot so delnice, tržna kapitalizacija, dolgovi, lastniški kapital in obveznosti Recordati Industria Chimica e Farmaceutica SpA Prihodki. Če iščete podrobnejše informacije o teh temah, na naših podstraneh nudimo obsežne analize:
- Recordati Industria Chimica e Farmaceutica SpA Prihodki
- Recordati Industria Chimica e Farmaceutica SpA Dobiček
- Recordati Industria Chimica e Farmaceutica SpA KGV
- Recordati Industria Chimica e Farmaceutica SpA Večkratnik prihodkov (KUV)
- Recordati Industria Chimica e Farmaceutica SpA EBIT
- Recordati Industria Chimica e Farmaceutica SpA Dividenda
- Recordati Industria Chimica e Farmaceutica SpA Delnice
- Recordati Industria Chimica e Farmaceutica SpA Tržna kapitalizacija
- Recordati Industria Chimica e Farmaceutica SpA Dolžniško financiranje
- Recordati Industria Chimica e Farmaceutica SpA Obveznosti
- Recordati Industria Chimica e Farmaceutica SpA Lastniški kapital
- Recordati Industria Chimica e Farmaceutica SpA AAQS
- Recordati Industria Chimica e Farmaceutica SpA zaposleni
- Recordati Industria Chimica e Farmaceutica SpA ROE
- Recordati Industria Chimica e Farmaceutica SpA ROA
- Recordati Industria Chimica e Farmaceutica SpA ROCE